Hypersensitivity News and Research RSS Feed - Hypersensitivity News and Research

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.
New drug receives FDA approval to reduce risk of cardiovascular death in adults with diabetes

New drug receives FDA approval to reduce risk of cardiovascular death in adults with diabetes

The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease. [More]
Study reveals why air pollutants cause some people to be at risk for atopic dermatitis

Study reveals why air pollutants cause some people to be at risk for atopic dermatitis

Tohoku University Graduate School of Medicine and Tohoku Medical Megabank Organization are pleased to announce the published results of a study into why air pollutants cause some people to be more susceptible to atopic dermatitis, a kind of skin inflammation. [More]
Excessive consumption of fatty foods could negatively affect cognitive functions in children

Excessive consumption of fatty foods could negatively affect cognitive functions in children

Chances are that children who eat excessive amounts of fatty foods will not only become obese, but will develop cognitive and psychiatric problems when they are older. [More]
New bio-photonic device aims to take drug hypersensitivity detection into new era

New bio-photonic device aims to take drug hypersensitivity detection into new era

Over 2.5 million people in Europe and more than 5.4 million Americans suffer from hypersensitivity to Beta Lactam Antibiotics (BLCs), the most commonly prescribed drugs that contain the penicillin family, with up to 10 percent of people reporting an allergy. [More]
Researchers discover brain signature that may help identify fibromyalgia patients

Researchers discover brain signature that may help identify fibromyalgia patients

University of Colorado Boulder researchers have discovered a brain signature that identifies fibromyalgia sufferers with 93 percent accuracy, a potential breakthrough for future clinical diagnosis and treatment of the highly prevalent condition. [More]
Research on naked mole-rats could pave way for new human pain therapies

Research on naked mole-rats could pave way for new human pain therapies

In injuries and inflammation, naked mole-rats do not develop normal hypersensitivity to temperature stimuli. [More]
Researchers propose new explanation for symptoms of fragile X syndrome

Researchers propose new explanation for symptoms of fragile X syndrome

Until recently, scientists thought they understood one of the underlying causes of fragile X syndrome, the most common inherited cause of intellectual disability in the United States. [More]
Research provides insight into link between chronic pain and anxiety

Research provides insight into link between chronic pain and anxiety

New research provides insight into a long-observed, but little-understood connection between chronic pain and anxiety and offers a potential target for treatment. [More]
New research aims to understand, manage contact lens discomfort

New research aims to understand, manage contact lens discomfort

Do you have dry eyes or other symptoms related to wearing contact lenses? If so you're not alone—up to 50 percent of contact lens wearers experience dryness or discomfort at least occasionally. [More]
Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Preclinical data on Selecta’s novel immune tolerance platform published in Nature Nanotechnology

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta’s research which demonstrate the broad potential applicability of Selecta’s novel immune tolerance platform. [More]
FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes. [More]
New non-drug approach may help manage pain in individuals receiving addiction treatment

New non-drug approach may help manage pain in individuals receiving addiction treatment

It's a Catch-22 with potentially deadly consequences: People trying to overcome addiction can't get treatment for their pain, because the most powerful pain medicines also carry an addiction risk. [More]
Japanese researchers suggest link between stimulus response and consciousness

Japanese researchers suggest link between stimulus response and consciousness

Japanese researchers centered at Nagoya University reveal a role for orexin neurons of the hypothalamus when mice respond to painful stimuli, and suggest a link between stimulus response and consciousness. [More]
Transplant drug rapamycin may reduce nerve damage, neuropathic pain after spinal cord injury

Transplant drug rapamycin may reduce nerve damage, neuropathic pain after spinal cord injury

New research in mice indicates that a drug commonly used to suppress the immune system in recipients of organ transplants may also reduce tissue damage and neuropathic pain after spinal cord injury. The findings are published in the Journal of Orthopaedic Research. [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
FDA approves Absorb GT1 BVS to treat coronary artery disease

FDA approves Absorb GT1 BVS to treat coronary artery disease

The U.S. Food and Drug Administration today approved the first fully absorbable stent to treat coronary artery disease. [More]
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]
IU researchers identify suite of genes that play role in nerve sensitivity

IU researchers identify suite of genes that play role in nerve sensitivity

Indiana University researchers have that found a suite of genes in both fruit flies and humans -- including one dubbed "smoke alarm" -- plays a role in nerve sensitivity. The study could help lead to new drug targets in pain management. [More]
New study identifies 40 genes susceptible to migraine

New study identifies 40 genes susceptible to migraine

Migraine is one of the most common neurological disorders and it affects 1 out of 7 people in the world. Painful and incapacitating, it has multi-factor origins, with the participation of environmental triggering factors and several altered genes in each individual. [More]
Zinbryta gets FDA approval for treating adults with relapsing forms of MS

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly. [More]
Advertisement
Advertisement